VFA
MDGL icon

Virtus Fund Advisers’s Madrigal Pharmaceuticals MDGL Stock Holding History

Virtus Fund Advisers’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$402K Buy
+4,382
New +$250K ﹤0.01% 351
2014
Q3 		– Sell
-141
Closed -$20K – 1591
2014
Q2 		$20K Buy
+141
New +$20.6K ﹤0.01% 2439

Other funds holding MDGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Virtus Fund Advisers's MDGL Position: Q4 2017 in Review

Virtus Fund Advisers opened a new position in Madrigal Pharmaceuticals (MDGL) in Q4 2017: 4,382 shares worth $402K. The stake represents ﹤0.01% of the portfolio and ranks #351 among its holdings. This is a return to the name: Virtus Fund Advisers previously reported a position in MDGL as recently as Q2 2014.

Virtus Fund Advisers first reported a position in MDGL in Q2 2014 and has held it in 2 quarters since. 91 funds tracked by Wall St. Rank hold MDGL as of Q4 2017.

  • Virtus Fund Advisers held 4,382 shares of Madrigal Pharmaceuticals worth $402K as of Q4 2017.
  • Madrigal Pharmaceuticals was a new Virtus Fund Advisers position in Q4 2017.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Virtus Fund Advisers's portfolio in Q4 2017, its #351 holding.
  • Virtus Fund Advisers first reported a position in Madrigal Pharmaceuticals in Q2 2014 and has held it in 2 quarters since.
  • 91 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2017.

Based on Virtus Fund Advisers's 13F filing for Q4 2017, filed 9 Feb 2018.